Qi Zhang 2014.

Study characteristics
Methods	Study design: secondary analysis of RCT Country: multiple ‐ most sites in USA and Canada, also sites in India, Iran, Pakistan and Tunisia Data collection period: December 2005 ‐ June 2010 Registry ID: ClinicalTrials.gov: NCT00689611
Participants	Number of participants: N = 225 Sample characteristics (at baseline): Age (mean): 54 years (SD 10); Sex (% male): 84.4% (190/225) Population category: chronic physical condition; Specific population: people who actively smoked (average ≥ 10 CPD in past year) who suffered a MI with ≥ 24 hours hospitalisation were recruited in the ZESCA (9 weeks bupropion versus placebo) Nicotine dependence: FTND bupropion 5.4 (SD 2.2), placebo 5.5 (SD 2.0);Baseline cigarettes per day: not measured; Motivation to quit: selected by motivation to quit
Interventions	Behavioural support for smoking cessation: prior to initiation of study medication, all participants received a standardised non‐pharmacologic smoking cessation intervention Pharmacological support for smoking cessation: 9 weeks of bupropion (150 mg once daily for 3 days, then 150 mg twice daily) or placebo Psychotherapeutic or psychoactive support for mental health or mood: received mood management – 109/225 participants included in analysis were in the bupropion group
Outcomes	Definition of cessation used: abstinence was biochemically validated by an exhaled carbon monoxide level of ≤ 10 ppm during all clinic visits; secondary endpoint of ZESCA trial was point‐prevalence smoking abstinence at 12 months; ‘persistent quitters’ defined as abstinence at all follow‐ups Cessation definition used for outcome(s) in this analysis: continuous abstinence Measure of biovalidation: expired CO (≤ 10 ppm) Definition of people who continued to smoke used: ‘smokers’ defined as reported smoking on at least 1 occasion Time point(s) at which follow‐up was conducted: 6 and 12 months Outcome category: Depression, Psychological Quality of Life (QoL) Outcome measure(s): Beck Depression Inventory II (BDI‐II) used in circulation abstract; EuroQol‐5D (EQ‐5D) used in main paper
Funding source	This ZESCA trial was funded by the Canadian Institutes of Health Research (Grant NCT64989) and the Heart and Stroke Foundation of Quebec
Author conflicts of interest	Dr. Eisenberg received funding from Pfizer Canada Inc., to conduct the Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post‐Acute Coronary Syndrome(EVITA) Trial (NCT00794573); all other authors have no potential conflicts to disclose
Notes	Outcome data source: Published data